Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL: Mirvetuximab Soravtansine vs Chemotherapy in Platinum-Resistant Ovarian Cancer with High FRα
2019-003509-80Phase 3Completed
- Sponsor
- ImmunoGen
- Start
- Jan 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more (2 arms), sponsored by ImmunoGen. Primary endpoints: Progression-free survival and Objective response rate. Started Jan 2020; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)malignant peritoneal neoplasm
Beyond the preview
Go deeper on 2019-003509-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003509-80.